Sanofi says Gaucher pill meets goals in late-stage tests
PARIS Feb 15 (Reuters) - Sanofi said on Friday its experimental pill for Gaucher disease met its main targets in two late-stage studies, which the French drugmaker will use to bolster its case for regulatory approval.
If approved, eliglustat tartrate could become the first-oral treatment for Gaucher disease, a rare genetic disorder affecting some 10,000 patients worldwide.
(Reporting by Elena Berton; Editing by Christian Plumb)
- Target holiday cyber breach hits 40 million payment cards |
- Housing, jobs data weaken, but overall economic picture still upbeat
- UPDATE 3-Saab wins Brazil jet deal after NSA spying sours Boeing bid
- Zuckerberg to sell Facebook shares worth about $2.3 billion |
- Special Report: Why Ukraine spurned the EU and embraced Russia